Digital Health Technologies (DHTs) in Clinical Trials: Key Points from the FDA’S Important Draft Guidance Date Published: Jan 27, 2022 Whitepaper Signant’s Bill Byrom discusses the FDA’s most recent guidelines regarding digital health technologies (DHTs), such as sensors and wearables as well as general computing platforms, when collecting health data from clinical trial patients. Readers will learn: The FDA’s position on BYOD in the context of DHTs The evidence supporting the use of sensors & wearables Data integrity considerations in the context of minimizing missing data and device, firmware, or software update Download Now Share: LinkedInTweet Recommended Resources 3 Themes and Takeaways From FDA’s Draft Guidance on DCTs Download Now Whitepaper Computerized Adaptive Tests Using PROMIS CAT Download Now Whitepaper The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper